Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers Squibb is a global biopharmaceutical company with a strong focus on immuno-oncology, a rapidly growing market where the company is a leader in drug development. The company's recent updates, including increased guidance, positive sentiment from multiple experts on its upcoming catalysts, and promising results from a competitor's related drug, demonstrate the potential for significant revenue growth and upside optionality in the coming years. This, coupled with cost management and a solid dividend, make BMY a compelling investment opportunity for investors seeking long-term growth and stability in the biopharmaceutical space.

Bristol-Myers Squibb is facing significant risks in its clinical trials, including potential delays or denials in regulatory approvals and the threat of new products or competitor innovations. Their increased dependence on the US market also poses a potential risk to future revenue growth. These factors, combined with a lower-than-average forward EV/EBITDA multiple of 9.4x, contribute to our negative outlook on the stock.